Open-house discount agreement for Sorafenib
Originaltitel der Bekanntmachung
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02
Opportunity Score
Warum diese Bewertung?
Chance
46 / 100
Komplexität
58 / 100
Risikofaktoren
The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...
Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Moderate opportunityWichtige Fakten
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house discount agreements for the medicinal product Sorafenib, ATC L01EX02.
- Supply-related pharmaceutical contract under German social law framework stated by the buyer.
Vollständige Zusammenfassung anzeigen
This is an open-house supply arrangement for pharmaceutical discount agreements on Sorafenib (ATC L01EX02) by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.11.2024 to 31.10.2026, with contract entry possible until 05.09.2026. Submission can be by handwritten paper originals or by qualified electronic signature via DTVP. No contract value is stated.
Risiken
The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...
Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...
Submission deadline in 8 days
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- The contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
Auftraggeber
Ort
München, DEU
Website
Auftraggeberprofil
Kennung
DE811695320
Tätigkeit
Health
Lose (1)
LOT-0001
Open-house discount agreement for Sorafenib
Single lot for non-exclusive open-house pharmaceutical discount agreements concerning Sorafenib (ATC L01EX02). The buyer states that identical, non-individually negotiable contracts are offered to all interested pharmaceutical companies meeting the eligibility condition. Performance is in Germany, Bavaria (DE212).
Ort
Dauer
Kategorie
Frist
Zuschlagsdetails
Siehe kurze Beschreibung
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02
Originale TED-Beschreibung
Siehe kurze Beschreibung
Vergabedetails
- Veröffentlichungsdatum
- 16 Sep 2024
- Sprachen
- German
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 557828-2024
Dokumente (2)
Ähnliche Ausschreibungen
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Warum diese Bewertung?
Chance
46 / 100
Komplexität
58 / 100
Risikofaktoren
The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...
Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications